Microsoft word - gbi healthcare marking tech_20100816_pr.doc
Innomech develops powerful ‘track and trace’ technology for healthcare markets
GB Innomech (Innomech), which specialises in the development of advanced automation
systems, is helping develop a powerful new low-cost approach to uniquely mark
pharmaceutical and related healthcare products and therefore improve product traceability.
The technique will allow faster identification and resolution of any manufacturing quality
problems but will also prove invaluable as an anti-counterfeit measure because the specific
coding and validation systems are almost impossible to copy.
Currently most components within diagnostic kits, medical devices and other healthcare
products and equipment are ‘stamped’ with a lot code at the point of manufacture. However,
these codes are of limited use for quality improvement unless products are produced in very
small batches. As a result, regulatory bodies across the world are now putting manufacturers
under increasing pressure to invest in much more sophisticated traceability systems, while
manufacturers are looking for effective ways to prevent the growing problem of counterfeiting
of pharmaceuticals and other healthcare products.
The breakthrough approaches being developed by Innomech will enable manufacturers to
mark products with a code that is either unique to the item or shared by only a small number
The codemark is an unobtrusive two-dimensional dot matrix identifier that is linked to a look-
up database. In effect the matrix code acts as a ‘key’ to access much more detailed
information, such as the specific batch codes of raw materials used during production, the
time of manufacture, the production line and so on. A version of the database could be
accessible online for anyone to verify the item is genuine
The codes can be printed or laser etched onto products, applied to virtually any substrate and
can even be added onto the surface of pharmaceutical capsules or coated tablets. Matrix
codes can be as small as 2 mm by 2 mm holding the code for up to 10 billion numbers. The
codes can be read by widely available readers or in many cases from a picture taken with
even the simplest camera phone, making them ideal in the battle against counterfeit
For example, a doctor in remotest Africa about to dispense a treatment course for malaria
could take a picture of the product packaging code, send it by SMS to a centralised online
database and within seconds have an auto-response to confirm the validity of the product and
be sure he/she is not dispensing an ineffective or even potentially fatal counterfeit product.
The integration of such techniques fits in well with Innomech’s business of providing
advanced automation and ensuring that high risk areas are thoroughly investigated through
feasibility studies. Ensuring the appropriate type of laser, which is suitable to the product and
is capable of being used as part of the overall automation solution is a key area of
“Innomech is now working with several clients to help adjust their manufacturing processes to
incorporate this powerful new approach and enable products to be much more easily marked
than has previously been possible,” said Steve Robertson, managing director of Innomech
Notes to editors: Background information on counterfeit medicines The World Health Organisation estimates around 50% of all medicines sold online are worthless counterfeits and in developing nations, fake tablets or capsules may account for as much as 30% of all drugs on the market [ref: www.who.int/mediacentre/factsheets/fs275/en/index.html ]. The risk these counterfeits pose is considerable. During the 1995 meningitis epidemic in the West Africa state of Niger over 50,000 people were inoculated with fake vaccines containing only tap water, resulting in 2,500 deaths [ref: www.nafdacnigeria.org/publichealth.html ]. And in 2005, during the H5N1 bird flu outbreak, the FDA issued several consumer warnings about the widespread availability of fake Tamiflu via the internet. About GB Innomech GB Innomech (Innomech) specialises in automating highly complex and labour-intensive manufacturing processes to maximise outputs, improve product quality and boost business performance. The company works with major international manufacturers in sectors such as pharmaceuticals, medical devices and environmental, as well as earlier-stage businesses looking to bring breakthrough technologies or products to market. Innomech has a growing market reputation for solving the toughest of manufacturing problems by the early identification and management of risk, often cross-fertilising technologies and techniques from a range of industry sectors. All projects from initial feasibility studies through to building production-scale machines are conducted to high specification pharmaceutical industry standards and are designed to comply with GAMP5, FDA and other international standards.
The company was founded in 1990, is based at The Innovation Centre in Witchford, north of Cambridge and was awarded The Queen’s Award for Enterprise 2009 to recognise its sustained growth in international markets. For additional information about GB Innomech please visit or contact: •
Press enquiries to Simon McKay on +44 (0)1353 741075 or email to email@example.com
All other enquiries to Steve Robertson at Innomech on +44 (0)1353 667394
Photographs Print quality JPEGs of the images below have been sent as a separate file attached to the original email or are also available on request from Simon McKay (details above):
Innomech is developing technologies to print or laser etch two-dimensional dot matrix identifier codes onto a variety of healthcare products. The image above shows a 2 mm x 2 mm matrix code printed onto the surface of drug capsules.
Adding 2D-matrix codes to drug capsules [shown above] or onto tablet coatings is one of the most powerful anti-counterfeiting measures available today. The specific codes and validation systems are virtually impossible to copy and within seconds doctors can validate the product’s authenticity via an online system.
Molecularly imprinted polymers for trace analysis Benoit Guieysse Biotechnology Dept., Lund University The analysis of trace contaminants almost always requires preliminary steps of sample concentration and purification. Concentration is often conducted by solid-phase extraction (SPE) using silica-based adsorbents, which at best select the contaminants based on their hydrophobic properties, an